In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advanced Diagnostics: Innovation, Reimbursement, And Coverage Challenges

Executive Summary

Developers of novel advanced diagnostics tests face many challenges that dramatically constrain both innovation and the ability to provide new tests to clinicians and patients. Recently, planned changes in pricing detailed in the Protecting Access to Medicare Act of 2014, and new guidelines on evidence development have been put forward and in some cases adopted – will these recent changes address the challenges?

You may also be interested in...



Patents After Myriad: Can cDNA Cover All The Bases?

Life sciences attorneys expect the Supreme Court’s ruling that isolated DNA is not patentable will invalidate thousands of patents; it is unclear whether medicinal molecules isolated from nature or made synthetically are impacted by the decision.

Biotech Industry Fears Fallout From Supreme Court’s Myriad Ruling; PTO Offers Guidance

Supreme Court unanimously holds that DNA isolated from the human body cannot be patented but cDNA, which is created in a laboratory, can; Patent and Trademark Office tells examiners to reject product claims drawn solely to naturally occurring nucleic acids or their fragments.

Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint

The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel